Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3748/wjg.v23.i11.1954 http://scihub22266oqcxt.onion/10.3748/wjg.v23.i11.1954 C5360636!5360636 !28373761     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28373761 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       World+J+Gastroenterol 2017 ; 23 (11 ): 1954-1963 Nephropedia Template TP {{tp|p=28373761 |t=2017. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management |pdf=|usr=}}{{28373761 }} gab.com Text Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management JO: World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=28373761 #FOAvip Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation as well as in the prevention and treatment of venous thromboembolism. However, similar to traditional anticoagulants, NOACs have the side effects of bleeding, including gastrointestinal bleeding (GIB). Results from both randomized clinical trials and observations studies suggest that high-dose dabigatran (150 mg b.i.d), rivaroxaban and high-dose edoxaban (60 mg daily) are associated with a higher risk of GIB compared with warfarin. Other risk factors of NOAC-related GIB include concomitant use of ulcerogenic agents, older age, renal impairment, Helicobacter pylori infection and a past history of GIB. Prevention of NOAC-related GIB includes proper patient selection, using a lower dose of certain NOACs and in patients with renal impairment, correction of modifiable risk factors, and prescription of gastroprotective agents. Overt GIB can be managed by withholding NOACs followed by delayed endoscopic treatment. In severe bleeding, additional measures include administration of activated charcoal, use of specific reversal agents such as idarucizumab for dabigatran and andexanent alfa for factor Xa inhibitors, and urgent endoscopic management. Twit Text FOAVip Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management ????World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=28373761 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28373761 #FOAvip English Wikipedia <ref>{{Cite pmid|28373761 }}</ref> Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management #MMPMID28373761 Cheung KS ; Leung WK World J Gastroenterol 2017[Mar]; 23 (11 ): 1954-1963 PMID28373761 show ga Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation as well as in the prevention and treatment of venous thromboembolism. However, similar to traditional anticoagulants, NOACs have the side effects of bleeding, including gastrointestinal bleeding (GIB). Results from both randomized clinical trials and observations studies suggest that high-dose dabigatran (150 mg b.i.d), rivaroxaban and high-dose edoxaban (60 mg daily) are associated with a higher risk of GIB compared with warfarin. Other risk factors of NOAC-related GIB include concomitant use of ulcerogenic agents, older age, renal impairment, Helicobacter pylori infection and a past history of GIB. Prevention of NOAC-related GIB includes proper patient selection, using a lower dose of certain NOACs and in patients with renal impairment, correction of modifiable risk factors, and prescription of gastroprotective agents. Overt GIB can be managed by withholding NOACs followed by delayed endoscopic treatment. In severe bleeding, additional measures include administration of activated charcoal, use of specific reversal agents such as idarucizumab for dabigatran and andexanent alfa for factor Xa inhibitors, and urgent endoscopic management. |Administration, Oral [MESH] |Anticoagulants/administration & dosage/*adverse effects/therapeutic use [MESH] |Atrial Fibrillation/*prevention & control [MESH] |Blood Coagulation Factors/agonists/antagonists & inhibitors [MESH] |Clinical Trials as Topic [MESH] |Endoscopy, Gastrointestinal [MESH] |Gastrointestinal Hemorrhage/*chemically induced/prevention & control/*therapy [MESH] |Helicobacter Infections/complications [MESH] |Humans [MESH] |Peptic Ulcer/chemically induced/complications [MESH] |Risk Factors [MESH]Gastrointestinal bleeding in patients on novel oral anticoagulants: Ri(epmc).pdf DeepDyve Pubget Overpricing